Candel Therapeutics . Full-time Employee Directory

Biotechnology ResearchMassachusetts, United States51-200 Employees

Candel Therapeutics is a clinical-stage biotechnology company based in Needham Heights, Massachusetts, focused on developing off-the-shelf multimodal biological immunotherapies that aim to elicit a systemic anti-tumor immune response. It operates two clinical-stage platforms built around genetically modified viruses: the HSV-based CAN-3110 (lead candidate) in an investigator-sponsored phase 1 trial for recurrent high-grade glioma, and the adenovirus-based CAN-2409 in phase 2/3 trials for NSCLC, borderline resectable pancreatic cancer, and localized non-metastatic prostate cancer. The company also uses the enLIGHTEN Discovery Platform, an HSV-based discovery platform for identifying new viral immunotherapies for solid tumors. Candel has pursued manufacturing development for CAN-3110 with Batavia Biosciences and has commercial and financing arrangements, including a collaboration with EVERSANA for a potential U.S. launch of CAN-2409 in localized prostate cancer and a royalty financing agreement with RTW Investments. The organization employs 51-200 people and is headquartered at 117 Kendrick Street, Suite 450, Needham Heights, MA 02494; its website is candeltx.com.

Sign up for free to view info

Company overview Email format